Reaction
Vexas Syndrome reporting signals
As of the last recalculation, Vexas Syndrome appears in 89 FAERS reports alongside 4 co-occurring drug terms. The strongest observed disproportionality signal is CANAKINUMAB (PRR 189.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Canakinumab | 8 | 189.9 | 190.0 |
| Anakinra | 11 | 176.8 | 176.9 |
| Tofacitinib Citrate | 7 | 135.4 | 135.5 |
| Baricitinib | 5 | 128.4 | 128.5 |